GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas.

GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas. Leuk Lymphoma. 2008 Sep; 49(9):1681-92.

View in: PubMed

subject areas

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
Granulocyte-Macrophage Colony-Stimulating Factor
Humans
Immunotherapy
Lymphoma, B-Cell
Recombinant Proteins
Rituximab
Treatment Outcome

authors with profiles

Parameswaran Venugopal